Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.
Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.
Gilbert Tang, MD, spoke to Cardiovascular Business about late-breaking data from the TRILUMINATE IDE trial. While early results were promising, these latest findings highlight the TriClip device's true value for the first time.
Data from nearly 9.9 million participants were included in the team’s final analysis. The group emphasized the important role governments can play in trying to reverse the world's reliance on these products.
Startup vendor FIRE1 completed patient enrollment in its U.S. early feasibility study for a heart failure remote monitoring device that directly measures fluid volume inside the IVC.
Cerebral protection devices, designed to limit the risk of stroke during transcatheter aortic valve replacement, may be especially helpful when patients undergo valve-in-valve TAVR.
Black patients are already less likely to receive LVADs or transplants compared to whites, and these inaccurate readings can further widen the disparities.
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
